Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • As biosimilars hit, EU...

    As biosimilars hit, EU pharma warns against blanket prescribing

    Written by supriya kashyap kashyap Published On 2017-03-11T10:02:19+05:30  |  Updated On 11 March 2017 10:02 AM IST
    As biosimilars hit, EU pharma warns against blanket prescribing

    London : European drug makers, faced with increasing competition from cut-price copies of complex biotech drugs, cautioned doctors to take care when switching patients from an established product to a so called biosimilar version.


    The complex nature of biological medicines, which are made inside living cells, means copies can never be exactly the same as the original. But a growing number of such drugs have now been approved in Europe as similar enough to do the job.


    The European Medicines Agency has to date approved two dozen biosimilars against just four in the United States.


    Late last month the first biosimilar cancer drug hit the European the market, with the launch of Celltrion's Truxima, a copy of Roche's blood cancer treatment Rituxan or MabThera.


    Truxima has been approved in all of Rituxan/MabThera's indications and governments around Europe are keen to see it used widely, in order to curb rising drug bills.


    Three industry associations representing branded drug firms, however, said in a joint statement that doctors should look at the circumstances of each individual patient before switching them from established drugs to cheaper biosimilars.


    "It is vital for a physician to balance the level of evidence against the level of risk or uncertainty in each particular case," the EFPIA, EBE and IFPMA associations said.


    "A 'one size fits all' approach is not appropriate."

    biosimilarscancer drugCelltrion's Truximadozen biosimilarsEuropean Medicines AgencyRituxan
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok